Pfiz­er’s PARP in­hibitor com­bo treat­ment pass­es pri­ma­ry end­point — but de­tails are slim

Pfiz­er ac­quired both Xtan­di and Talzen­na, a PARP in­hibitor, in its $14 bil­lion buy­out of Medi­va­tion in 2016.

And in its Phase III TA­LAPRO-2 study, it com­bined the two drugs to treat pa­tients with metasta­t­ic cas­tra­tion-re­sis­tant prostate can­cer, or mCR­PC for short, com­par­ing them to Xtan­di alone. Tues­day morn­ing, Pfiz­er said that study met its pri­ma­ry end­point of pro­gres­sion free sur­vival, get­ting a low­er haz­ard ra­tio than its pre-spec­i­fied one of 0.696. But it didn’t give many more de­tails.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER